Khiron Life Sciences has successfully attained, for the first time, full reimbursement by the NHS of costs associated with cannabis-based medication and clinic fees for a patient enrolled in Zerenia™ Clinics UK. The patient was referred to the team at Zerenia Clinics UK for assistance with evaluation and advice on cannabis-based treatment options.
This ground-breaking step validates Khiron's scientific and data-driven approach to demonstrate the efficacy, safety, and cost-effectiveness of CBMPs in the management of chronic conditions such as pain and anxiety. The Company, which continues to train doctors on the prescription of CBMPs, will be presenting its real-world evidence (RWE) at the upcoming International Congress on Clinical Trials on Cannabis to an international audience of medical doctors in London's Canary Wharf in mid-February.
Franziska Katterbach, President of Khiron Europe, comments: "There is a huge demand for medicinal cannabis in the UK. More than 1.4 million British self-medicate illegally with cannabis, half of whom medicate every day, with a total spend on illicit cannabis is an estimated £2.6 billion every year. On top of that, the estimated wait times for NHS specialist consultations range drastically, but in certain areas, can be up to nine months. We are prepared to work with the NHS and provide our outstanding clinical resources, medical cannabis products, and certified training tools to decrease wait times for patients and ensure access to life-changing medication. Having a route for patient reimbursement for cannabis-based medicinal products is an important pillar of our global strategy, which we just finally achieved with mandatory reimbursement in Colombia."